1. Home
  2. NXGL vs SXTP Comparison

NXGL vs SXTP Comparison

Compare NXGL & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

N/A

Current Price

$3.35

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Logo 60 Degrees Pharmaceuticals Inc.

SXTP

60 Degrees Pharmaceuticals Inc.

N/A

Current Price

$0.50

Market Cap

1.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NXGL
SXTP
Founded
1997
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
1.8M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
NXGL
SXTP
Price
$3.35
$0.50
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $3.70
AVG Volume (30 Days)
29.1K
★ 307.4K
Earning Date
11-16-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
24.00
★ 36.77
EPS
N/A
★ N/A
Revenue
★ $11,421,000.00
$1,005,471.00
Revenue This Year
$38.23
N/A
Revenue Next Year
$53.72
$70.00
P/E Ratio
★ N/A
N/A
Revenue Growth
31.46
★ 65.49
52 Week Low
$0.15
$0.34
52 Week High
$161.59
$8.62

Technical Indicators

Market Signals
Indicator
NXGL
SXTP
Relative Strength Index (RSI) 41.23 32.36
Support Level $3.31 N/A
Resistance Level $4.50 $1.01
Average True Range (ATR) 0.52 0.08
MACD 0.09 -0.01
Stochastic Oscillator 11.92 7.13

Price Performance

Historical Comparison
NXGL
SXTP

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About SXTP 60 Degrees Pharmaceuticals Inc.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

Share on Social Networks: